IMUNON's IMNN-001 Shows Promising Results in Phase 2 Ovarian Cancer Trial

IMUNON's IMNN-001 showed continued gains in overall survival in a Phase 2 ovarian cancer trial, with a 14.7-month improvement in median overall survival for women receiving the therapy plus chemotherapy. The results reinforce the drug's potential in newly diagnosed advanced ovarian cancer, a challenging cancer to treat with limited progress in standard therapies over the past three decades. IMNN-001 is a DNA-based IL-12 immunotherapy delivered directly into the tumor region using IMUNON's TheraPlas platform.